Financial Counselors Inc. Lowers Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Financial Counselors Inc. trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,846 shares of the company’s stock after selling 147 shares during the quarter. Financial Counselors Inc.’s holdings in IDEXX Laboratories were worth $763,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cranbrook Wealth Management LLC boosted its position in shares of IDEXX Laboratories by 7.0% in the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company’s stock worth $158,000 after purchasing an additional 25 shares during the period. Perigon Wealth Management LLC lifted its stake in shares of IDEXX Laboratories by 1.8% during the 4th quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company’s stock valued at $632,000 after buying an additional 26 shares in the last quarter. Summit Trail Advisors LLC boosted its holdings in IDEXX Laboratories by 3.3% in the 4th quarter. Summit Trail Advisors LLC now owns 810 shares of the company’s stock worth $335,000 after buying an additional 26 shares during the period. IFP Advisors Inc increased its stake in IDEXX Laboratories by 3.6% in the 4th quarter. IFP Advisors Inc now owns 903 shares of the company’s stock worth $373,000 after buying an additional 31 shares in the last quarter. Finally, Cape Cod Five Cents Savings Bank raised its holdings in IDEXX Laboratories by 0.5% during the third quarter. Cape Cod Five Cents Savings Bank now owns 6,344 shares of the company’s stock valued at $3,091,000 after acquiring an additional 32 shares during the period. Institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling

In other news, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by company insiders.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $415.87 on Friday. The company’s 50-day moving average price is $437.07 and its 200-day moving average price is $443.27. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The company has a market cap of $33.71 billion, a PE ratio of 38.98, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $548.88.

Analyst Upgrades and Downgrades

IDXX has been the subject of several research analyst reports. Barclays increased their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price for the company. Finally, Bank of America lifted their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.